PhRMA calls on USTR to be tough on unfair practices

The Office of the US Trade Representative (USTR)’s 2019 Special 301 Report – scheduled to be released this spring – brings critical attention to overseas intellectual property (IP) and market access challenges that harm American innovators, patients and workers.

In its 2019 Special 301 submission, lobbying group Pharmaceutical Research and Manufacturers of America (PhRMA encourages the Administration to take a tough stance in addressing the negative, unfair practices of certain countries, writes Megan Van Etten, senior director of public affairs at PhRMA, on The Catalyst blog

The 2018 Special 301 Report established the Administration’s commitment to leveling the playing field for American companies, particularly those, such as biopharmaceutical innovators, that rely on IP rights. PhRMA’s submission to this year’s report calls for continued work by the Administration to hold its trading partners accountable to mutually-established obligations.